Canaccord Genuity analyst Whitney Ijem has maintained their bullish stance on RYTM stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Whitney Ijem has given his Buy rating due to a combination of factors including Rhythm Pharmaceuticals’ strong performance in the second quarter of 2025, where the company exceeded topline expectations despite increased operational expenses. These expenses were primarily attributed to clinical trial costs, development activities, and marketing efforts, which are seen as strategic investments for future growth.
Additionally, the company is making significant progress in its launch readiness for setmelanotide in adult and pediatric endocrinology, with a focus on a specialty launch strategy. The management’s confidence in the potential of setmelanotide, particularly in the exploratory trial for Prader-Willi Syndrome (PWS), and the anticipation of future data readouts, further supports the positive outlook. The unchanged price target of $105 reflects the analyst’s confidence in the company’s strategic direction and growth potential.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $100.00 price target.
RYTM’s price has also changed dramatically for the past six months – from $60.010 to $90.010, which is a 49.99% increase.